Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among: 1 Perianal ...
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the ...
The data include new Phase 3 AFFIRM findings for SKYRIZI (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, as well as open-label extension analyses demonstrating long-term ...
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
Around it, AbbVie ABBV+1.49% also presented analyses of Skyrizi's open-label extension showing sustained endoscopic outcomes ...
ABIVAX's obefazimod showed 51% clinical remission vs. 10% placebo in 44-week UC trial, claiming largest phase 3 ...
Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a Phase 3b extension study to track the long term ...
The Crohn's & Colitis Foundation will host its 59th Annual Gala at the Edison Ballroom, featuring Broadway performances and celebrating 25 years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results